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PRESIDENTIAL ADDRESSChange you can count onRobert C. Robbins, MDThank you, John, for that kind introduction.
I want to begin by telling you what an exciting, meaning-
ful, and humbling experience it has been to serve as your
President for the past year.
I greatly appreciate all of the wonderful support that I
have received from so many of you, especially our past
President Robbin Cohen, as well as the members of the
Council and the staff of PRRI, John Blackstone, Heather
Nutter, Rebecca Bonsaint, and Crystal Beatrice. We are
richly blessed to have such a special organization with sim-
ply outstanding members and their supportive families.
I want to thank my family. Debbie, Clay, and Craig are
my foundation. They have each supported me despite the
years of long hours and absenteeism.
Debbie and I have been married for 27 years. She is my
best friend, and she gave up a successful law practice to ded-
icate herself to helping Clay, Craig, and me achieve our
hopes and dreams. Thank you for everything that you
have done for our family.
I also have been blessed with dedicated mentors, col-
leagues, and friends over the past 30 years, most of whom
have been agents of change and innovative pioneers. I can-
not possibly include everyone, but I would like to acknowl-
edge some key individuals.
James D. Hardy and Arthur C. Guyton, at University of
Mississippi, were my early mentors during medical school.
Dr Hardy was a true surgical pioneer who performed the
world’s first human lung transplant in Jackson in 1963
and the first human heart transplant in 1964 using a chim-
panzee donor. Steve Guyton’s father was an internationally
renowned researcher and dedicated teacher who should
have been awarded the Nobel Prize for his work. A special
thank you to the extraordinary group who trained me at
Stanford: Dr Shumway who agreed to train me, Bruce Reitz
who gave me my first and only real job that I have ever had,
Phil Oyer, Ed Stinson, Craig Miller, Scott Mitchell, Jim
Mark, Walter Cannon, and Vaughn Starnes. I feel blessed
to have been trained by these men and to have known
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and continue to make my job rewarding and the department
successful. Many of them are here today: Tom Burdon, Jim
Fann, Mike Fischbein, Ramin Beygui, Joe Shrager, Randy
Bolton, Richard Gregory, Richard Whyte, and Kai Ihnken.
I have great admiration for all of the residents whom I have
had the privilege to work with over the years, and I am
happy to see so many of you here today.
I also thank our all of the department’s staff, especially
my personal assistant, Beverly Bonfert, who for the past
15 years has kept me between the ditches on a daily
basis.
I am so grateful for the hard work that the program com-
mittee has done under the leadership of Gordon Cohen to
give us this year’s outstanding program. I did not knowGor-
don very well before this year, and I am pleased that he has
decided to take his talents to North Beach. I appreciate Gor-
don’s vision to personally convince President Emmert to be
with us this year. I also thank Arnie Millstein for joining us.
Preparing my thoughts for this address was difficult be-
cause I share the mentality that Dr Shumway promulgated
in his American Association for Thoracic Surgery Presiden-
tial Address entitled ‘‘Some thoughts from the other side of
the table, or the last presidential address.’’1 In those memo-
rable remarks, Dr Shumway noted the annual program
could accommodate 2 additional papers if the Presidential
Address was eliminated. Because we have not evolved to
Dr Shumway’s vision, please indulge me for the next few
minutes for some thoughts about our future.
Today, I would like to focus my comments on the topic of
change, it’s inevitability and the opportunity we all have to
embrace it and shape the future of the field of human en-
deavor we have all given somuch to and feel so passionately
about.
We have often heard that you are either improving or de-
clining, growing or decaying, living or dying.you cannot
simply stay the same. The Buddha tells us ‘‘Everything
changes. Nothing remains without change.’’ We all experi-
ence personal changes, including physical changes, philo-
sophical changes, social changes, financial changes,
family changes, and career changes.
How many of you have an iPad (Apple Inc, Cupertino,
Calif), a laptop, a smart phone? How many of you read
newspapers or books online? Do you ever use SKYPE (Lux-
embourg) to visit with your children? It seems unthinkable
that we once used rotary phones; listened to our music on
record players, 8-track tapes, or even Walkman cassette
players; and got our news from the nightly television
news and sports information from the newspaper box
scores. One of my regrets in life is that I didn’t have therdiovascular Surgery c Volume 145, Number 2 321
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munications technologies are rich with examples of rapid,
recent change that seems to be coming at an accelerating
pace. We as cardiothoracic surgeons have long been known
as pioneers and innovators. We practice in a field of medi-
cine, which, except for lung resection, did not exist 60 years
ago. Today, we perform operations on a daily basis that
could not have been imagined when our parents were
young. The exciting birth and rapid evolution of our field,
and the impact on individual lives and society as a whole
are some of the reasons many of us were drawn to cardio-
thoracic surgery.
There is ample evidence that as a group we are innova-
tors. However, like the rest of humankind, we can be resis-
tant to change. As the economist John Kenneth Galbraith
said, ‘‘Faced with the choice between changing one’s
mind and proving that there is no need to do so, almost ev-
eryone gets busy on the proof.’’
Maybe surgeons can be resistant to change because each
and every time one of us ‘‘commits surgery’’ as Dr Shum-
way would say, there is a chance that the patient can die.
It is only human to stick with what works. Once we have
a repertoire that works, we do not want to change our way
of performing critical operations. The upside can be un-
clear, and the downside can be severe. We are all artists,
convinced that the way we conduct operations is the abso-
lute best way to care for our patients.
Several years ago, there was a popular pizza commercial
in which a man was standing in his doorway anxiously
awaiting the arrival of 3 pizzas he had ordered. He’s excited
because not only was he allowed to order 3 pizzas for only
$5 each, but also he could mix and match toppings all he
wanted! In the commercial, he takes possession of 3 identi-
cal pepperoni pizzas and closes the door. His wife appears
and asks sarcastically why he always orders pepperoni
when his options are unlimited? He looks ashamed and an-
swers, ‘‘Because, I fear change.’’ Like the guy in the com-
mercial, most of us like things to be routine and predictable
in our lives, but as Roseanne Cash says, ‘‘The key to change
is to let go of fear.’’ I hope over the next few minutes that I
can encourage each of us to let go of fear, and not only be
open to change but also to lead change in the areas of edu-
cation, research, and clinical care.
CHANGES IN EDUCATION
Medical education in general and cardiothoracic surgical
education specifically are currently in a time of great evolu-
tion and change.
There are 168 hours in a week, and for most of us in this
room, our surgical training consisted of 7 to 10 years of ev-
ery other or every third night in the hospital on call, spend-
ing more than 100 hours per week in the hospital. Whether
you agree or disagree with the much-debated rationale for
shorter work hours, the 80-hour work week is here to stay322 The Journal of Thoracic and Cardiovascular Surgand will likely become even more proscriptive. First, we
must understand and accept this change. We might not
like it, but we understand it. Second, we must embrace
the challenge of training the best surgeons possible given
these inevitable restrictions.
Simulation
To deal with the reduction in patient contact produced by
work-hour restrictions, we must improve the efficiency and
efficacy of the education of our students, residents, and fel-
lows by further evolving the use of simulation to develop
technical and decision making skills. Jim Fann has been
an innovator in minimally invasive cardiac operations and
simulation and continues to refine the simulation process.
He is currently using a full cardiopulmonary bypass system
for coronary and valvular procedures to assess the efficacy
of this approach. I believe that the attendings and patients
will be able to determine trainees who have spent significant
time in intensive simulation. The impact will be visible, and
these are changes we can and should embrace.
Studying the Film
We must also do a better job of preparing our trainees for
excellence in all 6 core competencies of their curriculum:
medical knowledge, technical abilities, professionalism,
systems use, team care, and ethics. I envision that elite train-
ing programs in the future will use advanced, multiangled
cameras to film every cardiothoracic case performed by
a trainee. Just as in the National Football League, there
will be a dedicated full-time video coordinator to break
down and grade the films and to review each operation.
Both the trainee and attending will be miked so that a run-
ning commentary of the operation can be used for educa-
tional advancement and departmental entertainment. I am
certain that when residents perform a particularly smooth
move, they will look over the drape and proclaim, ‘‘Go
ahead and rack me because that the move will surely
make the ESPN Top 10 Plays of the Day.’’
Atul Gawande2 recently wrote an article for The New
Yorker in which he forwarded the concept that surgeons
should consider using coaches because all professional ath-
letes have coaches. I believe that we as surgical educators
should all take the oath of the Positive Coaching Alliance
and be committed to inspiring greatness in our trainees
through positive coaching in all of the core competencies
and lead by example. Training the next generation of
leaders in cardiothoracic surgery may be our most impor-
tant contribution to society, and we must embrace and
lead the inevitable change that will come in the domain of
cardiothoracic surgical education.
TECHNIQUES AND TECHNOLOGIES
The fundamental advancement of the field of cardio-
thoracic surgery has been so rapid because true pioneersery c February 2013
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research to discover new knowledge to improve the
health of patients. The development of cardiopulmonary
bypass, intra-aortic balloon pumps, heart and lung trans-
plantation, myocardial and neurologic protection strate-
gies, single lung ventilation, minimally invasive surgical
approaches, percutaneous valves, and smaller more effec-
tive left ventricular assist devices are all well-known ex-
amples of advances in our field that have improved the
outcomes of the operations we are privileged to perform
daily. These were changes driven by colleagues with
vision.
I am also certain that there will continue to be ad-
vances in devices that we all use, including percutaneous
mitral valve replacement, percutaneously delivered lead-
less pacemakers, percutaneously delivered and powered
left ventricular assist devices, and even less invasive pro-
cedures that will be performed in hybrid rooms that will
permit completion angiograms for all coronary artery by-
pass cases. We have developed a system in collaboration
with the chief of electrophysiology and department of
mechanical engineering that I believe may transform
the treatment of atrial fibrillation. Virtually every proce-
dure we do in the future will use image-guided therapies
with even more advanced imaging technologies than
those we have come to rely on today. Moreover, I believe
there will be major advances from the domains of geno-
mics, systems biology, bioengineering, bioinformatics,
and stem cell research.
GENOMICS AND BIOINFORMATICS
The human genome project took 10 years and 3 billion
dollars to map the entire genome of 1 single individual.
Moore’s law is a well-known computer science observation
that ‘‘computing power’’ as a function of speed and transis-
tor density doubles approximately every 18 months. I be-
lieve advances in genomic sequencing will follow
a similar curve going forward: The value of obtaining an en-
tire human genome in 10 years for $3 billion has now been
replaced with sequencing an entire genome in 48 hours for
less than $1000. This rapid progression has eclipsed the rate
of progress predicted by Moore’s law because if this tech-
nology had followed Moore’s law, today it would cost $5
million dollars to sequence a single human genome. Some
experts believe that this cost will soon be less than $50
per patient and that most health systems will eventually
pay patients to have their genomic data to guide the future
practice of medicine. I am certain that everyone in this
room will be able to carry their own genomic digital data
on their smart phone within the next decade. Or maybe
we will all be ‘‘chipped,’’ and first responders and clinical
caregivers will be able to read our histories with secret de-
coder rings. Change is inevitable whether you agree with it
or not. The challenge we face is to shape the changes inThe Journal of Thoracic and Caways we think will benefit patients and future generations
of cardiothoracic surgeons.
Genetic sequencing of entire populations has already be-
gun in places such as Iceland, where the Icelandic Parlia-
ment passed legislation to create a medical database,
including genetic data. Genomic-guided therapies for lung
cancer and coronary artery disease will be customized to
the patient’s genetic makeup. However, we need to have
more focused research designed to better understand what
this genetic information means for each patient. Sophisti-
cated bioinformatic analysis of genetic data must be com-
bined with phenotypic data, including environmental,
proteomic, metabolomic, and epigenetic factors that may
affect an individual patient’s health. The same challenge es-
sentially is being addressed in business settings under the
heading of ‘‘The Big Data Problem.’’ Simply, ‘‘Big Data’’
is the aggregation of disparate sources of information and
the analysis of more complete data sets with powerful,
computer-based analytic tools. It is a model that bears scru-
tiny. In Eric Topol’s recent book The Creative Destruction
of Medicine, he describes how the digital revolution will
create better health care.
INDUCIBLE PLURIPOTENT STEM CELLS
In the area of stem cell research, I believe embryonic
stem cells and inducible pluripotent stem (IPS) cell biology
will have powerful effects on the advancement of the treat-
ment of human diseases.
Our group has worked for more than 10 years on car-
diac stem cell biology, and we were recently awarded
a $20 million grant from the California Institute for Re-
generative Medicine that will help us be the first group
in the world to inject human embryonic stem cells into
the human heart.
The process of producing IPS cells was discovered by
Yakamana in 2005. Adult somatic cells, such as fibroblast
from the skin and more recently blood cells, can be pro-
grammed through gene therapy to revert back to a plurip-
otent or embryonic state and then directly differentiated
to become the desired cell, such as heart cells or brain
cells. The use of IPS cells for therapeutic interventions
to treat heart failure, diabetes, or Parkinson’s disease
holds great promise because these are autologous cells
that will not be rejected. In addition, the use of IPS cells
avoids the moral and ethical issues associated with em-
bryonic stem cells. Our valued collaborators Qian and
colleagues,3 at the Gladstone Institute in San Francisco,
have developed a technique that removes the IPS cell
step and directly differentiates adult fibroblasts to cardi-
omyocytes. Moreover, Qian and colleagues recently dem-
onstrated that this technique can be used in vivo to turn
cardiac fibroblasts into cardiomyocytes and therefore
set the stage for future repair of human myocardial
damage.rdiovascular Surgery c Volume 145, Number 2 323
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tially powerful uses of IPS cells beyond therapeutic inter-
ventions. The first is to use these cells to discover novel
mechanisms of disease processes and to identify new tar-
gets for the development of drugs or antibodies to treat
diseases such as congestive heart failure. One could
imagine conducting human clinical trials in a Petri dish
in the near future to determine whether new drugs are ef-
fective and efficacious in the perturbation of targets im-
portant in certain disease processes. We plan to develop
IPS cell lines from patients with Marfan syndrome to
test the efficacy of important new mechanisms for the de-
velopment of aortic aneurysms through a Mir 29–depen-
dent pathway, which was recently discovered and
published by Merk and colleagues4 at Stanford. The other
platform for the use of IPS cells will be in drug screening
for toxicity. Cardiac toxicity is a major limitation in the
development of drugs. The pre-animal screening of every
drug that is ingested for cardiac toxicity is currently per-
formed in Chinese hamster ovary cells to assess calcium
channel function and then impute possible cardiac toxic-
ity from these primitive screening tests.
I believe that every drug that is developed for human use
soon will be tested in a platform that uses human IPS cells
that have been differentiated to beating human cardiac cells.
The use of patch clamping techniques and other automated
and scalable technologies to determine electrocardio-
graphic abnormalities, such as prolonged QT syndrome,
one of the most important and lethal drug-induced arrhyth-
mias, will be possible using this IPS cell platform.
Cisapride, a multibillion dollar drug widely used for the
treatment of gastric dysmotility, was removed from the mar-
ket because of death from prolonged QT syndrome that was
not discovered in the primitive hamster cell screening that
was performed. The use of an IPS cell screening platform
could have avoided these deaths and saved the drug com-
pany billions of dollars.
Our group, under the leadership of Joe Wu, seeks to de-
velop 1000 IPS cell lines from patients with dilated and hy-
pertrophic cardiomyopathies, coronary artery disease, atrial
fibrillation, Marfan syndrome, and a variety of other known
cardiovascular diseases. We will build this library from old
and young patients, men and women, and all races and eth-
nicities to determine the efficacy and safety of drugs not
only in normal beating cardiac cells but also in cardiac cells
from patients with well-defined diseases.
CARDIOTHORACIC CARE DELIVERY
Just as we should focus our energy on finding more effi-
cient and effective ways to train the next generation of car-
diothoracic surgeons, I believe that we should also focus on
improving clinical care in a milieu where the inevitability of
major changes will evolve in our health care system. The
United States generates $16 trillion dollars per year in gross324 The Journal of Thoracic and Cardiovascular Surgdomestic product, the government collects $2.2 trillion
dollars in Federal taxes and spends $3.8 trillion dollars
annually (that is right, the US Government spends approx-
imately $10 billion dollars every day), thereby adding $1.6
trillion dollars to our national debt each year, which has now
reached $16 trillion dollars. There are $24.4 trillion in obli-
gations for current Medicare participants above and beyond
projected revenues from their payroll taxes, benefit taxes,
premium payments, and assets of the Medicare trust fund.
This is simply not sustainable, and change is certainly
needed in this domain and is inevitable.
A little closer to home, according to theWorld Health Or-
ganization, total health care spending in the United States
was 15.2% of its gross domestic product in 2008, the high-
est rate in the world.
Yet, despite having the most expensive health care sys-
tem in the world, the United States ranked last overall com-
pared with 6 other industrialized countries in a study
conducted by the Commonwealth Fund and published in
June 2010. The study attempted to measure health care de-
livery across a range of parameters, including quality and
efficiency. In brief, it said the United States stands out for
not getting good value for its health care dollars, ranking
last despite spending more than $7000 per capita on health
care in 2007. The Netherlands, which ranked first overall
among the 7 countries included in the study, spent less
than $4000.
In the clinical domain, there are 3 areas that will require
deep commitment over the coming years. Quality, cost, and
customer servicewill be used not only to judge performance
but also to be the parameters by which we are paid. There-
fore, I encourage all of us to become more involved and
aligned with our hospitals to better understand the financial
balance sheet of our cardiovascular service lines. I predict
that it will be extremely difficult for any of us to earn the
level of income that we consider reasonable without signif-
icant alignment with our hospitals. This is certainly true in
some academic centers and large health care systems such
as Kaiser, where alignment between the professional and
hospital technical revenues and the expenses are common-
place. It is likely that most of us will practice cardiothoracic
surgery in an integrated system in the future and that man-
aging both hospital and outpatient costs will be important to
all of us as members of a larger team.
We will need to achieve the highest quality outcomes at
the lowest possible cost to remain relevant and competitive.
Our quality data have been extensively tracked and scruti-
nized for approximately 2 decades, and despite the fact
that we are operating on patients who are sicker with
more comorbidities, the results for all cardiothoracic oper-
ations have improved over the past 2 decades; the 2011 na-
tional mean operative mortality for coronary artery bypass
grafting was 2.3%, which is truly remarkable. However,
we will need to continue to look for ways to improve allery c February 2013
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once we are paid on the basis of our results, we will become
more conservative in patient selection and will ultimately
serve as the gatekeepers for the providers, and de facto ra-
tioning will be achieved by the government. Moreover, I an-
ticipate in the near future that wewill each receive a detailed
cost analysis for how much it costs the hospital to care for
our patients, and those who achieve the best quality out-
comes for the lowest cost will be financially rewarded and
will remain competitive. We should all look for technologic
interventions that will help us achieve our objectives of
higher quality at lower costs.
In the near future, stethoscopes may be replaced with
handheld miniature echocardiography devices. These de-
vices currently cost approximately $6000, but the price
will certainly decrease as the market becomes more com-
petitive. We have recently funded a pilot study to give 10
cardiac transplant recipients these handheld devices, train
them to acquire satisfactory images of their left ventricles,
and to email us these images frequently with the objective
of reducing the number of hospital visits and endomyocar-
dial biopsies, thereby reducing costs. This is change that
will require work with multidisciplinary teams to deliver
the best care possible to our patients. We will need to invest
in technologic solutions, such as the Toyota Lean (Torrance,
Calif) and GE Six Sigma (Fairfield, Conn) methodologies to
improve our efficiency and efficacy to remain competitive.
The construction and maintenance of sophisticated bioin-
formatics datasets will be complemented by the adaptation
of so-called ‘‘cloud-based’’ computing resources and any-
where, anytime display and delivery mechanisms. We will
be able to leverage technology to follow patients’ biometric
data wirelessly and meet with them by video clinics from
their home computers or smart phones.
We are developing such a system at Stanford called the
‘‘Cardinal Commitment,’’ which we believe will improve
patient care quality and reduce cost.
STRATEGIC PLANNING
Finally, there will be changes in our association over
the next decade. To guide the process of rational,The Journal of Thoracic and Cathoughtful deliberate change in our organization, the
council has approved a request to move forward with
a strategic planning process that will develop a roadmap
for the future of the Western Thoracic Surgical Associa-
tion. I have asked Robbin Cohen to help me lead this pro-
ject over the next several months in collaboration with
a consultant group that specializes in health care strategic
planning. You will all receive a questionnaire that will
provide important data to help the working group through
the planning process.
We can count on change and should lead change that will
produce better trained cardiothoracic surgeons, innovative
discoveries, and improved outcomes for our patients. We
must be careful to make changes that are thoughtful and
strategic, and not change just to follow the latest fad. We
need to change for the better. We should be careful to avoid
strategies like those that led to New Coke (The Coca-Cola
Company, Atlanta, Ga) or Tiger’s new golf swing. I believe
that technology will be the key enabling leverage that we
will use to fulfill our missions, but the care of the future
must be high touch as well as high tech. Abraham Vergh-
ese, one of our Stanford colleagues and author of the great
novel Cutting for Stone, emphasizes the importance of the
physical examination and taking the time to listen to the
hopes and dreams of our patients. We are all so blessed
and privileged to be cardiothoracic surgeons. I believe that
we can invent the future of our field, and that it will be
a future full of change for good, change that we as surgeons,
but more important, our patients and their loved ones can
count on.
Thank you for your patience and attention.References
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